Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
The TRANSCEND CLL 004 trial represents the most promising data of CAR T-cell therapy – liso-cel – in chronic lymphocytic leukemia (CLL), a disease where CAR T therapy has been particularly challenging due to impaired T-cell fitness. Only 18% of patients achieved complete remission, while another 29% achieved partial remission, although many of these responding patients seemed to show durable responses. The future of CAR T-cells in CLL remains uncertain. The trial was simultaneously published in The Lancet.
